Envestnet Asset Management
ACTU

Envestnet Asset Management’s Actuate Therapeutics ACTU Stock Holding History

Envestnet Asset Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,465
Closed -$83.3K – 4491
2024
Q4 		$83.3K Buy
+10,465
New +$85.4K ﹤0.01% 4233

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NU
Northwestern University Evanston, Illinois $63.3M AUM 0.76% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Envestnet Asset Management's ACTU Position: Q1 2025 in Review

Envestnet Asset Management sold out of Actuate Therapeutics (ACTU) in Q1 2025, closing a stake of 10,465 shares — an estimated $83.3K sold.

Envestnet Asset Management first reported a position in ACTU in Q4 2024 and held it in 1 quarter. The position peaked at $83.3K in Q4 2024. 25 funds tracked by Wall St. Rank hold ACTU as of Q1 2025.

  • Envestnet Asset Management reported no remaining Actuate Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Envestnet Asset Management sold 10,465 Actuate Therapeutics shares in Q1 2025, an estimated $83.3K.
  • Envestnet Asset Management first reported a position in Actuate Therapeutics in Q4 2024 and held it in 1 quarter.
  • Envestnet Asset Management's Actuate Therapeutics position peaked at $83.3K in Q4 2024.
  • 25 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2025.

Based on Envestnet Asset Management's 13F filing for Q1 2025, filed 29 Apr 2025.